pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
All content for pharmaphorum Podcast is the property of pharmaphorum and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown
pharmaphorum Podcast
29 minutes
3 weeks ago
Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown
At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug pricing. This was followed by similar announcements from AstraZeneca and Merck. But are these deals substantive policy or PR sleight of hand?
In today’s episode of the pharmaphorum podcast, host Jonah Comstock invites Hogan Lovells Partner Alice Valder Curran back to the show to help get to the bottom of that question, as well as to talk a little about TrumpRx. And this time she's brought along her colleague Elizabeth Jungman who gives us the skinny on the FDA's new priority voucher system and what exactly the government shutdown means for the pharma industry.
Despite the many press releases, oval office announcements, and guidance documents, there’s still a lot we don’t know about all these topics. But Curran and Jungman help clarify what we do know so far and provide context and analysis to fill in the gaps. For the rest, we’ll have to wait and see what US policymakers have in store.
Tune in for the whole illuminating conversation.
pharmaphorum Podcast
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
